Emergent BioSolutions received a $52.7 million contract modification from HHS's ASPR exercising Option Year 7 under its 10-year ACAM2000 supply contract. The modification covers delivery of ACAM2000 smallpox vaccine doses, related ancillaries, and diluent replacement lots in June 2026, with remaining diluent due by December 2026. The award supports the U.S. government's preparedness and vaccine stockpile efforts.

Agreement details:

  • Agreement type: Contract modification exercising Option Year 7 under 10-year ACAM2000 supply contract
  • Counterparty: ASPR (U.S. Department of Health and Human Services)
  • Signed / Effective: Jun 26 2026 / same
  • Duration / Termination: Through Dec 2026
  • Reason: Supply ACAM2000 vaccine for U.S. preparedness stockpile

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.